Clinical trial

A Study of TAS-120 in Patients With Metastatic Breast Cancer

NCT04024436

Study summary

ClinicalTrials.gov

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Futibatinib Normalized identity: futibatinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Futibatinib plus Fulvestrant Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-01-28

PhasePHASE2

Conditions

Metastatic Breast Cancerunresolved

FGFR 1 High Amplificationunresolved

FGFR2 Amplificationunresolved

Interventions

FutibatinibDRUG · verified · RxNorm: futibatinib

Futibatinib plus FulvestrantDRUG

Sponsors & collaborators

Taiho Oncology, Inc.lead sponsor

Mapped research locations

BostonMassachusetts, United States3 MadridSpain2 RomaItaly2 PortoPortugal2 HoustonTexas, United States1 DallasTexas, United States1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1 BarcelonaSpain1 TampaFlorida, United States1 PhoenixArizona, United States1 JacksonvilleFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04024436 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.